Literature DB >> 16267775

The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.

Casie Kelly-Quintos1, Andrea Kropec, Stacy Briggs, Claudia L Ordonez, Donald A Goldmann, Gerald B Pier.   

Abstract

BACKGROUND: The staphylococcal surface polysaccharide poly N-acetyl glucosamine (PNAG) is a target for killing and protective antibody in animals. We investigated the human antibody response and specificity of binding and opsonic antibodies for different epitopes on PNAG in serum samples from patients with cystic fibrosis (CF) colonized and not colonized with Staphylococcus aureus.
METHODS: Serum samples from patients with CF colonized and not colonized with S. aureus were used to compare levels and specificities of binding and opsonic antibodies to native PNAG (>95% acetylation) and deacetylated PNAG (dPNAG, approximately 15% acetylation).
RESULTS: Colonized patients had higher killing activity mediated by opsonic antibody than did noncolonized patients in a PNAG-specific opsonophagocytic assay (P<.0001) but no difference in average levels of antibody to either PNAG or dPNAG by enzyme-linked immunosorbent assay. Killing activity in serum samples of the colonized patients correlated with the level of IgG specific to dPNAG more than to native PNAG. dPNAG and PNAG shared expression of the epitopes binding opsonic antibody, as evidenced by comparable inhibition of opsonophagocytic killing by both antigens. Affinity-purified antibodies specific to dPNAG were superior in mediating opsonic killing.
CONCLUSION: Human antibodies to PNAG that mediate opsonic killing bind primarily to the nonacetylated epitopes of this antigen, which indicates that these antigenic determinants are the dominant targets of the functional human antibody response to staphylococcal PNAG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267775     DOI: 10.1086/497604

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Role of a putative polysaccharide locus in Bordetella biofilm development.

Authors:  Gina Parise; Meenu Mishra; Yoshikane Itoh; Tony Romeo; Rajendar Deora
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

2.  Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine.

Authors:  Casie Kelly-Quintos; Lisa A Cavacini; Marshall R Posner; Donald Goldmann; Gerald B Pier
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 3.  The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG.

Authors:  David Skurnik; Colette Cywes-Bentley; Gerald B Pier
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

4.  Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection.

Authors:  Andrea Kropec; Tomas Maira-Litran; Kimberly K Jefferson; Martha Grout; Sarah E Cramton; Friedrich Götz; Donald A Goldmann; Gerald B Pier
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 5.  Progress toward a Staphylococcus aureus vaccine.

Authors:  Robert S Daum; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2011-12-20       Impact factor: 9.079

Review 6.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

7.  Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine.

Authors:  Nuno Cerca; Kimberly K Jefferson; Tomas Maira-Litrán; Danielle B Pier; Casie Kelly-Quintos; Donald A Goldmann; Joana Azeredo; Gerald B Pier
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

8.  Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors.

Authors:  Tessie B McNeely; Najaf A Shah; Arthur Fridman; Amita Joshi; Jonathan S Hartzel; Ravi S Keshari; Florea Lupu; Mark J DiNubile
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.

Authors:  Marina L Gening; Tomás Maira-Litrán; Andrea Kropec; David Skurnik; Martha Grout; Yury E Tsvetkov; Nikolay E Nifantiev; Gerald B Pier
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

10.  Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl beta-1,6 glucosamine specific antibody production using biofilm-embedded bacteria.

Authors:  M M Pérez; A Prenafeta; J Valle; J Penadés; C Rota; C Solano; J Marco; M J Grilló; I Lasa; J M Irache; T Maira-Litran; J Jiménez-Barbero; L Costa; G B Pier; D de Andrés; B Amorena
Journal:  Vaccine       Date:  2009-02-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.